Clinical Study of the GEM Combined Use Gamma Delta T Immune-Cells Treatment an Excision Impossible Paccreatic Cancer

Clinical Study of the GEM Combined Use Gamma Delta T Immune-Cells Treatment an Excision Impossible Paccreatic Cancer - Clinical Study of the GEM Combined Use Gamma Delta T Immune-Cells Treatment an Excision Impossible Paccreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013794

Enrollment

Registered

2014-06-02

Start date

2014-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Interventions

Gamma Delta T Immune-Cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patients that the diagnosis of the cancer was obtained by histological diagnosis or cytodiagnosis in principle. 2)An outpatients over 20 years old. 3) Performance States (PS) is 0 to 3. 4) The good prognosis will be expected 3 months or more until administration starting point. 5) In principle, keep major organ function is kept as follows; Number of White Blood Cell>4,000/mm3, <12,000/mm3. Number of neutrophil>2,000/mm3. Platelet count>100,000/mm3. Number of hemoglobin>10.0g/dL. Serum GOP and GPT< upper limits of institution x 2. Total serum bilirubin<1.5mg/dL. Serum creatinine<1.5mg//dL. But in the case of not meet a condition, reason came from existing disease(Cancer). Lead principal investigator can add those patients to this study by his judgment. 6) The patient that agreement was obtained in a document than the person himself in response to a name of disease condition notice. 7) Women; Pregnant possibility is denied by surgery, radiation or menopause, or possibility of pregnant can be reduced by the use of the approved antifertility method from the administration starting point to after 3 month of study finished.

Exclusion criteria

Exclusion criteria: 1) The patients with autoimmune disease 2) The patients with complications having poor control. (An infection, diabetes, hypertension, ischemic heart disease, cerebral infraction, etc.). 3) The patients egnancy nursing mother and the pregnant likelihood(possibility). 4) The patients history of the drug allergy. 5) The patients with double cancer. 6) The patients with HIV antibody-possitive. 7) The patients with locally advanced pancreatic cancer in need of radiotherapy . 8) Other, the patients is judged inadequate by research contact person

Design outcomes

Primary

Measure	Time frame
Progression-free Survival	—

Countries

Japan

Contacts

Public ContactAtsushi Ochiai

Tomishiro Central Hospital Clinical Study Support Center

ochiai.tomishirocentral.hp@gmail.com098-891-6375

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026